Literature DB >> 25964857

Reversal of natural killer cell exhaustion by TIM-3 blockade.

Anne Gallois1, Ines Silva2, Iman Osman2, Nina Bhardwaj1.   

Abstract

Natural killer (NK) cells are innate immune cells that become progressively exhausted in advanced stage cancer, crippling their ability to execute antitumor functions. We previously characterized the nature of NK cell exhaustion in metastatic melanoma patients, reporting a correlation with high expression of TIM-3. Blockade of this immune checkpoint molecule reversed the exhausted phenotype and improved NK cell function.

Entities:  

Keywords:  Tim-3; exhaustion; immune checkpoint; melanoma; natural killer cells

Year:  2015        PMID： 25964857      PMCID： PMC4353130          DOI： 10.4161/21624011.2014.946365

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.

Authors:  Lishomwa C Ndhlovu; Sandra Lopez-Vergès; Jason D Barbour; R Brad Jones; Aashish R Jha; Brian R Long; Eric C Schoeffler; Tsuyoshi Fujita; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

Authors:  Sophia Platonova; Julien Cherfils-Vicini; Diane Damotte; Lucile Crozet; Vincent Vieillard; Pierre Validire; Pascale André; Marie-Caroline Dieu-Nosjean; Marco Alifano; Jean-François Régnard; Wolf-Herman Fridman; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  Cancer Res       Date:  2011-06-27       Impact factor: 12.701

4.  Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Authors:  Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-02-11       Impact factor: 11.151

5.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

Authors:  Emilie Mamessier; Aude Sylvain; Marie-Laure Thibult; Gilles Houvenaeghel; Jocelyne Jacquemier; Rémy Castellano; Anthony Gonçalves; Pascale André; François Romagné; Gilles Thibault; Patrice Viens; Daniel Birnbaum; François Bertucci; Alessandro Moretta; Daniel Olive
Journal:  J Clin Invest       Date:  2011-08-15       Impact factor: 14.808

6.  Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.

Authors:  Saar Gill; Adrianne E Vasey; Alysha De Souza; Jeanette Baker; Aaron T Smith; Holbrook E Kohrt; Mareike Florek; Kenneth D Gibbs; Keri Tate; David S Ritchie; Robert S Negrin
Journal:  Blood       Date:  2012-04-27       Impact factor: 22.113

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

9.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

10.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307
  10 in total
  36 in total

Review 1.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

2.  IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Authors:  Rossana Tallerico; Costanza M Cristiani; Elina Staaf; Cinzia Garofalo; Rosa Sottile; Mariaelena Capone; Yago Pico de Coaña; Gabriele Madonna; Eleonora Palella; Maria Wolodarski; Valentina Carannante; Domenico Mallardo; Ester Simeone; Antonio M Grimaldi; Sofia Johansson; Paolo Frumento; Elio Gulletta; Andrea Anichini; Francesco Colucci; Gennaro Ciliberto; Rolf Kiessling; Klas Kärre; Paolo A Ascierto; Ennio Carbone
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 3.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

Review 4.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

5.  TIM-3: a crucial regulator of NK cells in pregnancy.

Authors:  Yanhong Li; Dajin Li; Meirong Du
Journal:  Cell Mol Immunol       Date:  2017-09-11       Impact factor: 11.530

6.  Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.

Authors:  Maite Alvarez; Federico Simonetta; Jeanette Baker; Antonio Pierini; Arielle S Wenokur; Alyssa R Morrison; William J Murphy; Robert S Negrin
Journal:  JCI Insight       Date:  2019-06-18

Review 7.  NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

Review 8.  Modulation of innate immunity in the tumor microenvironment.

Authors:  Elena Gonzalez-Gugel; Mansi Saxena; Nina Bhardwaj
Journal:  Cancer Immunol Immunother       Date:  2016-06-25       Impact factor: 6.968

9.  Minimal PD-1 expression in mouse and human NK cells under diverse conditions.

Authors:  Sean J Judge; Cordelia Dunai; Ethan G Aguilar; Sarah C Vick; Ian R Sturgill; Lam T Khuat; Kevin M Stoffel; Jonathan Van Dyke; Dan L Longo; Morgan A Darrow; Stephen K Anderson; Bruce R Blazar; Arta M Monjazeb; Jonathan S Serody; Robert J Canter; William J Murphy
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 10.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.